Impact of COVID-19 Outbreak on Neuraminidase Inhibitor, Global Market Research Report 2020

1 Neuraminidase Inhibitor Market Overview

• 1.1 Product Overview and Scope of Neuraminidase Inhibitor
• 1.2 Covid-19 Impact on Neuraminidase Inhibitor Segment by Type
  • 1.2.1 Global Neuraminidase Inhibitor Sales Growth Rate Comparison by Type (2021-2026)
  • 1.2.2 Zanamivir
  • 1.2.3 Oseltamivir
  • 1.2.4 Peramivir
  • 1.2.5 Laninamivir
• 1.3 Covid-19 Impact on Neuraminidase Inhibitor Segment by Application
  • 1.3.1 Neuraminidase Inhibitor Sales Comparison by Application: 2020 VS 2026
  • 1.3.2 Hospital Pharmacies
  • 1.3.3 Drug Stores
  • 1.3.4 Retail Stores
  • 1.3.5 Others
• 1.4 Covid-19 Impact on Global Neuraminidase Inhibitor Market Size Estimates and Forecasts
  • 1.4.1 Global Neuraminidase Inhibitor Revenue 2015-2026
  • 1.4.2 Global Neuraminidase Inhibitor Sales 2015-2026
  • 1.4.3 Neuraminidase Inhibitor Market Size by Region: 2020 Versus 2026
• 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
  • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
  • 1.5.2 Covid-19 Impact: Commodity Prices Indices
  • 1.5.3 Covid-19 Impact: Global Major Government Policy
• 1.6 The Covid-19 Impact on Neuraminidase Inhibitor Industry
• 1.7 COVID-19 Impact: Neuraminidase Inhibitor Market Trends

2 Covid-19 Impact on Global Neuraminidase Inhibitor Market Competition by Manufacturers

• 2.1 Global Neuraminidase Inhibitor Sales Market Share by Manufacturers (2015-2020)
• 2.2 Global Neuraminidase Inhibitor Revenue Share by Manufacturers (2015-2020)
• 2.3 Global Neuraminidase Inhibitor Average Price by Manufacturers (2015-2020)
• 2.4 Manufacturers Neuraminidase Inhibitor Manufacturing Sites, Area Served, Product Type
• 2.5 Neuraminidase Inhibitor Market Competitive Situation and Trends
  • 2.5.1 Neuraminidase Inhibitor Market Concentration Rate
  • 2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue
  • 2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
• 2.7 Primary Interviews with Key Neuraminidase Inhibitor Players (Opinion Leaders)

3 Covid-19 Impact on Neuraminidase Inhibitor Retrospective Market Scenario by Region

• 3.1 Global Neuraminidase Inhibitor Retrospective Market Scenario in Sales by Region: 2015-2020
• 3.2 Global Neuraminidase Inhibitor Retrospective Market Scenario in Revenue by Region: 2015-2020
• 3.3 North America Neuraminidase Inhibitor Market Facts & Figures by Country
  • 3.3.1 North America Neuraminidase Inhibitor Sales by Country
  • 3.3.2 North America Neuraminidase Inhibitor Sales by Country
  • 3.3.3 U.S.
  • 3.3.4 Canada
• 3.4 Europe Neuraminidase Inhibitor Market Facts & Figures by Country
  • 3.4.1 Europe Neuraminidase Inhibitor Sales by Country
  • 3.4.2 Europe Neuraminidase Inhibitor Sales by Country
  • 3.4.3 Germany
  • 3.4.4 France
  • 3.4.5 U.K.
  • 3.4.6 Italy
  • 3.4.7 Russia
• 3.5 Asia Pacific Neuraminidase Inhibitor Market Facts & Figures by Region
  • 3.5.1 Asia Pacific Neuraminidase Inhibitor Sales by Region
  • 3.5.2 Asia Pacific Neuraminidase Inhibitor Sales by Region
  • 3.5.3 China
  • 3.5.4 Japan
  • 3.5.5 South Korea
  • 3.5.6 India
  • 3.5.7 Australia
  • 3.5.8 Taiwan
  • 3.5.9 Indonesia
  • 3.5.10 Thailand
  • 3.5.11 Malaysia
  • 3.5.12 Philippines
  • 3.5.13 Vietnam
• 3.6 Latin America Neuraminidase Inhibitor Market Facts & Figures by Country
  • 3.6.1 Latin America Neuraminidase Inhibitor Sales by Country
  • 3.6.2 Latin America Neuraminidase Inhibitor Sales by Country
  • 3.6.3 Mexico
  • 3.6.3 Brazil
  • 3.6.3 Argentina
• 3.7 Middle East and Africa Neuraminidase Inhibitor Market Facts & Figures by Country
  • 3.7.1 Middle East and Africa Neuraminidase Inhibitor Sales by Country
  • 3.7.2 Middle East and Africa Neuraminidase Inhibitor Sales by Country
  • 3.7.3 Turkey
  • 3.7.4 Saudi Arabia
  • 3.7.5 U.A.E

4 Covid-19 Impact on Global Neuraminidase Inhibitor Historic Market Analysis by Type

• 4.1 Global Neuraminidase Inhibitor Sales Market Share by Type (2015-2020)
• 4.2 Global Neuraminidase Inhibitor Revenue Market Share by Type (2015-2020)
• 4.3 Global Neuraminidase Inhibitor Price Market Share by Type (2015-2020)
• 4.4 Global Neuraminidase Inhibitor Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Covid-19 Impact on Global Neuraminidase Inhibitor Historic Market Analysis by Application

• 5.1 Global Neuraminidase Inhibitor Sales Market Share by Application (2015-2020)
• 5.2 Global Neuraminidase Inhibitor Revenue Market Share by Application (2015-2020)
• 5.3 Global Neuraminidase Inhibitor Price by Application (2015-2020)

6 Company Profiles and Key Figures in Neuraminidase Inhibitor Business

• 6.1 GlaxoSmithKline
  • 6.1.1 Corporation Information
  • 6.1.2 GlaxoSmithKline Description, Business Overview and Total Revenue
  • 6.1.3 GlaxoSmithKline Neuraminidase Inhibitor Sales, Revenue and Gross Margin (2015-2020)
  • 6.1.4 GlaxoSmithKline Products Offered
  • 6.1.5 GlaxoSmithKline Recent Development and Response to COVID-19
• 6.2 Gilead Sciences
  • 6.2.1 Gilead Sciences Corporation Information
  • 6.2.2 Gilead Sciences Description, Business Overview and Total Revenue
  • 6.2.3 Gilead Sciences Neuraminidase Inhibitor Sales, Revenue and Gross Margin (2015-2020)
  • 6.2.4 Gilead Sciences Products Offered
  • 6.2.5 Gilead Sciences Recent Development and Response to COVID-19
• 6.3 F. Hoffman-La Roche
  • 6.3.1 F. Hoffman-La Roche Corporation Information
  • 6.3.2 F. Hoffman-La Roche Description, Business Overview and Total Revenue
  • 6.3.3 F. Hoffman-La Roche Neuraminidase Inhibitor Sales, Revenue and Gross Margin (2015-2020)
  • 6.3.4 F. Hoffman-La Roche Products Offered
  • 6.3.5 F. Hoffman-La Roche Recent Development and Response to COVID-19
• 6.4 BioCryst
  • 6.4.1 BioCryst Corporation Information
  • 6.4.2 BioCryst Description, Business Overview and Total Revenue
  • 6.4.3 BioCryst Neuraminidase Inhibitor Sales, Revenue and Gross Margin (2015-2020)
  • 6.4.4 BioCryst Products Offered
  • 6.4.5 BioCryst Recent Development and Response to COVID-19
• 6.5 Daiichi Sankyo
  • 6.5.1 Daiichi Sankyo Corporation Information
  • 6.5.2 Daiichi Sankyo Description, Business Overview and Total Revenue
  • 6.5.3 Daiichi Sankyo Neuraminidase Inhibitor Sales, Revenue and Gross Margin (2015-2020)
  • 6.5.4 Daiichi Sankyo Products Offered
  • 6.5.5 Daiichi Sankyo Recent Development and Response to COVID-19

7 Neuraminidase Inhibitor Manufacturing Cost Analysis

• 7.1 Neuraminidase Inhibitor Key Raw Materials Analysis
  • 7.1.1 Key Raw Materials
  • 7.1.2 Key Raw Materials Price Trend
  • 7.1.3 Key Suppliers of Raw Materials
• 7.2 Proportion of Manufacturing Cost Structure
• 7.3 Manufacturing Process Analysis of Neuraminidase Inhibitor
• 7.4 Neuraminidase Inhibitor Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

• 8.1 Marketing Channel
• 8.2 Neuraminidase Inhibitor Distributors List
• 8.3 Neuraminidase Inhibitor Customers

9 Market Dynamics

• 9.1 Market Trends
• 9.2 Opportunities and Drivers
• 9.3 Challenges
• 9.4 Porter's Five Forces Analysis

10 Global Market Forecast

• 10.1 Global Neuraminidase Inhibitor Market Estimates and Projections by Type
  • 10.1.1 Global Forecasted Sales of Neuraminidase Inhibitor by Type (2021-2026)
  • 10.1.2 Global Forecasted Revenue of Neuraminidase Inhibitor by Type (2021-2026)
• 10.2 Neuraminidase Inhibitor Market Estimates and Projections by Application
  • 10.2.1 Global Forecasted Sales of Neuraminidase Inhibitor by Application (2021-2026)
  • 10.2.2 Global Forecasted Revenue of Neuraminidase Inhibitor by Application (2021-2026)
• 10.3 Neuraminidase Inhibitor Market Estimates and Projections by Region
  • 10.3.1 Global Forecasted Sales of Neuraminidase Inhibitor by Region (2021-2026)
  • 10.3.2 Global Forecasted Revenue of Neuraminidase Inhibitor by Region (2021-2026)
• 10.4 North America Neuraminidase Inhibitor Estimates and Projections (2021-2026)
• 10.5 Europe Neuraminidase Inhibitor Estimates and Projections (2021-2026)
• 10.6 Asia Pacific Neuraminidase Inhibitor Estimates and Projections (2021-2026)
• 10.7 Latin America Neuraminidase Inhibitor Estimates and Projections (2021-2026)
• 10.8 Middle East and Africa Neuraminidase Inhibitor Estimates and Projections (2021-2026)

11 Research Finding and Conclusion

12 Methodology and Data Source

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources
• 12.3 Author List